Soft tissue sarcomas (STSs) are comparatively rare malignant tumors with poor prognosis. STSs predominantly arise from mesenchymal differentiation. MicroRNA-34b/c, the transcriptional targets of tumor suppressor p53, possesses tumor suppressing property. Hypermethylation of miR-34b/c has been associated with tumorigenesis and the progression of various cancers. To determine whether aberrant miR-34b/c methylation occurs in STSs, we quantitatively evaluated the methylation level of miR-34b/c in 57 STS samples and 20 cases of peripheral blood from healthy volunteers serving as normal controls by using matrix-assisted laser desorption ionization time-offlight mass spectrometry. We found that miRNA34b/c is more frequently methylated in STSs (0.157 ± 0.028) than in normal controls (0.098 ± 0.012, p = 0.038). Furthermore, the methylation levels of CpG_1.2.3, CpG_4.5.6.7, and CpG_11.12.13 of miR-34b/c were significantly higher in the STS group than in the normal control group (p b 0.001). No significant differences in the methylation levels within miR-34b/c were observed between specific reciprocal translocations in STSs and nonspecific reciprocal translocations in STSs (0.146 ± 0.039 vs. 0.168 ± 0.035, p N 0.05). The methylation levels of miR-34b/c in STSs were associated with clinical stage. The methylation levels of CpG_1.2.3, CpG_4.5.6.7, CpG_9.10, CpG_11.12.13, and CpG_14 in tumor-stage III/IV tissues were significantly higher than those in tumor-stage I/II tissues. Our findings indicated that DNA hypermethylation of the miR-34b/c is a relatively common event in STSs and is significantly correlated with late clinical stage in patients with STSs. Hypermethylation of the miR-34b/c may be pivotal in the oncogenesis and progression of STSs and may be a potential prognostic factor for STSs.
Introduction
Soft tissue sarcomas (STSs) are a group of mesenchymal origin malignant tumors characterized by highly biologic heterogeneity with respect to clinical behavior, morphological features, phenotype, and genetics. STSs encompass more than 50 distinct histological tumor subtypes. STSs occur relatively rarely and accounts for approximately 1% of malignant tumors (Ilaslan et al., 2010; Panotopoulos et al., 2014) . Patients with STSs have poor prognosis because of rapid metastasis and poor response to treatment. Although therapy has improved over the years, mortality remains fairly high. Traditionally, STSs are mainly classified into two categories according to the characteristics of the tumor genetics. One type is specific reciprocal translocations in STSs (SRTSs) and is characterized by simple karyotypes, which are chromosomal specific translocations and fusion gene formation, such as synovial sarcoma (SS), Ewing's sarcoma/peripheral primitive neuroectodermal tumor (ES/pPNET), dermatofibrosarcoma protuberan (DFSP), alveolar soft part sarcoma (ASPS) and myxoid liposarcoma (ML) . The other type is nonspecific reciprocal translocations in STSs (NRTSs) and is characterized by complicated karyotypes, which include the nonspecific chromosomal rearrangements, loss of heterozygosity and copy number alteration of DNA, such as pleomorphic rhabdomyosarcoma (PRMS), leiomyosarcoma (LMS), pleomorphic liposarcoma (PL), undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (FS) (Mertens et al., 2010) .
Previous studies have identified that genomic alterations, including the amplification or point mutation of oncogenes and the methylation or deletion of tumor suppressor genes (e.g., MDM2 amplification, P53 mutation, and PTEN methylation), are involved in the carcinogenesis of subtype-specific STSs (Barretina et al., 2010; Hettmer et al., 2014; Ware et al., 2014; Yin et al., 2013) . Moreover, p53 mutations were detected in 25.6% of STSs, the date has suggested that p53 mutations may be involved in the oncogenesis of STS (Yin et al., 2012) . By contrast, epigenetic alterations such as DNA methylation is an alternative mechanism of gene inactivation that occurs in the process of tumor progression and thus changes gene expression level without altering the DNA sequence (Liu et al., 2013; Zhu et al., 2012) . Similar to genetic mutations, transcriptional silencing owing to gene promoter CpG unit methylation is stably inherited by the next cell generation and may therefore enable the clonal expansion of a cell population with a selective advantage during tumor progression. Existing studies have shown that various tumor suppressor genes are frequently methylated in STSs and contribute to tumorigenesis. For example, epigenetic silencing of tumor suppressor gene BMP2 via CpG hypermethylation fosters tumor growth and progression in rhabdomyosarcoma, and the suppression of BMP2 by epigenetic silencing may be critical in the genesis of rhabdomyosarcoma (Wolf et al., 2014) . The hypermethylation of a novel tumor suppressor gene ASS1 promoter was detected and was strongly associated with ASS1 protein deficiency within myxofibrosarcoma, which was linked to increased tumor stage and grade, and independently predicted worse survival (Huang et al., 2013) . From what has been discussed above, identifying the molecular markers and pathogenesis of STSs, especially the detection of abnormal methylation, may be useful for the diagnosis and therapeutic regimens of STSs.
MicroRNAs (miRNAs) are a highly conserved class of small non-coding single-stranded RNAs that transcriptionally or posttranscriptionally regulate the level of gene expression through specific binding at regulatory regions in multicellular organisms. MiRNAs are involved in many basic biological and physiological regulatory processes, including cell differentiation, proliferation, apoptosis, stress response, and inflammation (Anwar and Lehmann, 2014; Kishore et al., 2014) . Epigenetic inactivation is one of the factors that influenced the regulatory mechanism of microRNAs. The transcription of miRNA as a protein-encoding gene might be inactivated by promoter hypermethylation. Widespread miRNA is dysregulated in STSs by changes in epigenetic silencing or protein expression, thus resulting in cellular malignant transformation (Diao et al., 2014; Karnuth et al., 2014) . Among the various miRNAs, the miR-34b/c gene, which localizes to chromosome 11q23.1 and belongs to the miR-34 family, shares a common primary transcript and acts as a potential tumor suppressor that is directly regulated by p53 (Corney et al., 2007; Wong et al., 2011; Zhang et al., 2014) . MiR-34b/c is involved in mediated cellular responses, such as cell cycle arrest (Yan et al., 2014) , apoptosis, and metabolic regulation (Zhang et al., 2014) . The reduced or deleted expression of miR-34b/c might contribute to diverse human cancers because of the aberrant CpG island methylation of its promoter (Beresneva et al., 2013; Nadal et al., 2013; Ng et al., 2014; Wu et al., 2014; Xie et al., 2014) . However, only one study has reported the methylation of miR-34b/c gene promoters in STS cell lines and tissue samples (Vogt et al., 2011) , but the methylation level of the miR-34b/c individual CpG unit and the exact function of DNA hypermethylation of miR-34b/c in STSs remains unclear.
In the present study, we accordingly therefore hypothesized whether miR-34 b/c CpG island aberrant methylation preferentially occurs in STSs and correlates with clinical parameters. To address these problems, we quantitatively evaluated the methylation level of the miR-34b/c individual CpG unit by using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) with 57 STS subjects, and then assessed the association between the methylation status of every CpG unit within the miR-34b/c and the clinicopathologic features of the patients with STSs. Results indicated that DNA hypermethylation of the miR-34b/c is a relatively common event in STSs and is significantly correlated with late clinical stage in patients with STSs. Hypermethylation of the miR-34b/c may be pivotal in the oncogenesis and progression of STSs and may be a potential prognostic factor for STSs.
Materials and methods

Ethics statement
Written informed consent was obtained from all participating patients in the study. This study was approved by the Research Ethics Committee at the First Affiliated Hospital of Shihezi University School of Medicine, PR China. The experiment was conducted in accordance with the ethical guidelines of the Declaration of Helsinki. All specimens were handled and made anonymous according to the ethical and legal standards.
Sarcoma tissue samples
We analyzed a total of 57 eligible FFPE tissue samples from a collection of STS patients registered in the Department of Pathology, The First Affiliated Hospital of Shihezi University School of Medicine, China, during 1976 to 2010. No restrictions regarding sex, age and disease stage were set. We excluded such patients who had undergone surgery (except diagnostic biopsy), chemotherapy, radiotherapy or any blood transfusion in the preceding six months before recruitment. The diagnoses of all original slides, including hematoxylin-eosin (HE) and immunohistochemistry staining from each case, were confirmed by two experienced pathologists. Each paraffin block was reviewed to assure that at least 70% of the tumor cells were present before sectioning and DNA extraction. Patients with STS subtypes were composed of 28 cases of SRTSs (5 cases of SS, 11 cases of ES/pPNET, 8 cases of DFSP, 1 case of ASPS, and 3 cases of ML) and 29 cases of NRTSs (1 case of PRMS, 5 cases of LMS, 1 case of PL, 18 cases of UPS, and 4 cases of FS). A total of 20 cases of peripheral blood collected in ethylenediaminetetraacetic acid (EDTA) were obtained from healthy volunteers serving as normal controls. In this study, various clinic-pathological characteristics of patients with STSs were investigated as follows. There were 35 (64.1%) males and 22 (38.6%) females in the case group. The age was 45.74 ± 6.69 (mean ± SD) years for the STS samples. The samples included 14 (24.6%) well-differentiated patients (G1), 14 (24.6%) moderately differentiated patients (G2), and 29 (50.8%) poorly differentiated patients (G3). 30 (65.2%) were classified as stage I/II and 16 (34.8%) as stage III/IV.
Isolation of genomic DNA
Total genomic DNA was extracted from the 57 FFPE STS tissues by means of proteinase K lysis and subsequent phenol-chloroform extraction. Twenty sections (5 μm each) from each FFPE tissue specimen were shredded with 1.5 ml of xylene in a 2 ml centrifugation tube placed upside down. The sections were applied to mix up the samples for 5 min, followed by mixing at 10 min in a 55°C water-bath. After centrifugation (5 min at 10,000 rpm), supernatants were removed. The cell pellets were washed with 1.5 ml of absolute ethanol and air-dried for evaporation of residual ethanol. The samples were lysed overnight at 60°C with 250 μl of lysis buffer (50 mM Tris pH 8.4, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.5% [v/v] Tween 20) and 50 μl of proteinase K (20 mg/ml) in a thermomixer. Proteinase K was inactivated (5 min, 95°C). High molecular weight DNA extraction was performed by phenol-chloroform methods as previously described (Dietrich et al., 2013) . After elution in 30 μl of elution buffer, genomic DNA was isolated from 20 healthy human peripheral blood used as normal controls by using standard phenol-chloroform extraction methods as previously described (Di Pietro et al., 2011) . DNA concentrations were measured using a NanoDrop Instrument (Thermo Scientific, Wilmington, DE, USA). As internal control, all purified genomic DNA samples were successfully tested by polymerase chain reaction with human β-globin primers for: 5′-CAGACACCATGGTGCACCTGAC-3′ and rev: 5′-CCAATA GGCAGAGAGAGTCAGTG-3′, indicating that the suitable quality and quantity of DNA can be used to detect the profile of miR-34b/c methylation. The eluted genomic DNA was stored at − 20°C until used as a template for the following test.
Bisulfite treatment
Genomic DNA was treated with sodium bisulfite using an EZ-96 DNA methylation kit (Zymo Research) according to manufacturer's recommendations with minor modifications. This process converts the nonmethylated cytosine residues to uracil, whereas the methylated cytosine remains unchanged. Briefly, we add 5 μl of M-dilution buffer to 10 μl DNA sample in a conversion plate and then adjust the total volume to 50 μl with water. We mix each sample by pipetting up and down. The mixture was incubated for 15 min at 37°C. After the above incubation, 100 μl of the prepared CT-conversion reagent was added to each sample and then mixed. This reaction mix was repeatedly heated between 95°C for 30 s and 55°C for 15 min in a PCR machine for 20 cycles followed by the washing and elution steps.
PCR and in vitro transcription
We identified the sequence of has-miR-34b/c CpG island (CGI) with the use of the UCSC genome browser (http://genome.ucsc.edu/) (chr11:110888379-110889102, %GC = 58.1 and Obs/ExpCpG = 0.73, Fig. 1 ). We then analyzed the CpG density and CpG sites of target sequences of has-miR-34b/c with extreme precision for the PCR primer design. One primer set was designed for the methylation analysis of the has-miR-34b/c by using EpiDesigner software (http://www. epidesigner.com). When the primers were designed, we added a T7 promoter tag (23 bp) and 8 bp insert to reverse the primer for in vivo transcription. After which, a 10 mer tag was added to the forward primer to balance the PCR primer length. We used the following primer pairs: miR-34b/c tag-forward, 5′-aggaagagagGTTATATGGATGGAGGGG TTTTAT-3′ and T7-reverse, 5′-cagtaatacgactcactatagggagaaggctACTACC ATCAAAACAAAACACAACA-3′. Subsequently, 2 μl of bisulfite-treated DNA was amplified by PCR as previous described (Lodygin et al., 2008) . The PCR product was treated by adding 1.7 μl of nuclease free water (Sequenom) and 0.3 μl of shrimp alkaline phosphatase (SAP; Sequenom). The reaction was incubated at 37°C for 20 min, after which SAP was inactivated for 5 min at 85°C.
We used 2 μl of SAP-treated PCR mixture as a template in a total volume 7 μl transcription reaction (all reagents from Sequenom). In vivo transcription and T cleavage were simultaneously performed at 37°C for 3 h, and then the product sample was purified. Further experimental details have been previously described (Coolen et al., 2007) .
MALDI-TOF-MS measurements
Using MassARRAY Nanodispenser robotically dispensed 22 nl of cleavage reaction onto silicon chips preloaded with matrix (SpectroCHIP, Sequenom). The DNA methylation status was quantitatively detected, and mass spectra were recorded using MALDI-TOF MS (Sequenom, San Diego, USA). Methylation data of individual units were generated by the EpiTyper v1.0.5 software (Sequenom).
Statistical methods
We used hierarchied cluster analysis to compare the methylation levels of miR-34b/c CpG units between STSs and normal control and to identify sites with a statistically significant difference by using Cluster 3.0 software and TreeView software. We then used Kruskal-Wallis test and Mann-Whitney test to analyze the difference in methylation levels. The significance level was set as a p value of less than 0.05. Statistical analysis was performed using the Mann-Whitney test to compare the methylation rate among SRTSs, NRTSs and normal control. Given that repeated hypothesis tests caused a type-one error α to expand, we should redefine the inspection level. The correction formula was α′ = α / N ('N' was the number of inspection), N = n(n − 1) / 2 ('n' was the number of groups for inspection), be α′ = 2α / n(n − 1) and α′ = 2 * 0.05 / 3 * (3 − 1) = 0.017. Thus, significance was set as a p value of less than 0.017. The statistical analyses were performed using the Statistical Package for the Social Science (SPSS) (IBM Corp, Armonk, NY) version 17.0.
Results
Frequent epigenetic silencing of miR-34b/c in STSs
We performed quantitative high-throughput analysis of DNA methylation patterns by using the MassARRAY system within the miR-34b/c CpG island, which contains 22 CpG sites. The methylation patterns of the miR-34b/c CpG island were studied in all the samples collected from STSs (n = 57) and normal controls (n = 20). A region of the miR-34b/c that is 280 base pairs in length and contains 22 CpG sites that could be divided into 8 CpG units was examined using a MassARRAY system. In essence, not all spectral changes could be detected because some fragments were either too small or too large, thus exceeding the available mass window. The length of the fragment may also influence the result of observation. Among these CpG units, 1 CpG unit (6 CpG sites) did not yield successful measurements. The final data set consisted of 7 CpG units (16 CpG sites) from 77 samples. Moreover, 82% of the CpG units yielded successful measurements and had good results for N90% of the samples.
We conducted a hierarchical clustering of the CpG unit methylation and the combined tumor and normal control to explore any natural groupings in this data set (Fig. 2) . Hierarchical cluster analysis of CpG units reveals two primary clusters: one cluster contains CpG_9.10, CpG_4.5.6.7, CpG_11.12.13, CpG_8, and CpG_14, was identified to have a higher methylation level, whereas the other contains CpG_1.2.3 and CpG_15.16. The corresponding CpG units tended to cluster together, showing similar intragenic methylation patterns. The observed patterns in the cluster analyses show that methylation patterns of normal control are notably different from those observed in STS tissues.
The results of methylation quantification methodology indicate that different degrees of methylation changes were detected in the target region of miRNA34b/c gene among 57 STSs and 20 normal controls. The overall methylation level within the target region of miRNA34b/c was statistically higher in STSs than in normal control (0.157 ± 0.028 vs. 0.098 ± 0.012, p = 0.038) (Fig. 3A) . The results demonstrate the occurrence of aberrant methylation of miRNA34b/c in STS samples and indicate that miRNA34b/c is abundantly methylated in STSs. The relationship between overall methylation level of miRNA34b/c and clinicopathologic features was further evaluated. There were significant association between overall methylation level of miRNA34b/c and gender, tumor TNM stage. However, there were no significant association between overall methylation level of miRNA34b/c and age, location of the primary tumor, tumor grade, tumor size, and tumor different histology, as shown in Table 1 .
Difference in methylation level of miR-34b/c between SRTSs and NRTSs
The difference in the quantitative methylation patterns of every CpG unit within the miR-34b/c between the 28 SRTSs and the 29 NRTSs was further evaluated. Overall, high degrees of methylation in miR-34b/c genes have been observed in SRTSs compared with normal controls (0.146 ± 0.039 vs. 0.098 ± 0.012, p = 0.023). The aberrant methylation level of miR-34b/c was significantly higher in NRTSs than in normal controls (0.168 ± 0.035 vs. 0.098 ± 0.012, p = 0.042) (Fig. 3B) . However, no statistical differences were observed in methylation patterns between SRTSs and NRTSs in the miR-34b/c genes (p N 0.05). As regards the CpG unit of miR-34b/c, the mean methylation levels at CpG_1.2.3, CpG_4.5.6.7, CpG_8, CpG_9.10, CpG_11.12.13, CpG_14, and CpG_15.16 were based on the differences between SRTSs (mean methylation = 18.05%, 10.55%, 15.0%, 10.29%, 9.33%, 20.29%, 18.33%, respectively) and NRTSs (mean methylation = 13.35%, 16.48%, 23.25%, 11.54%, 16.04%, 25.64%, 11.0%, respectively) (p N 0.05).
Methylation levels at individual CpG islands along the miR-34b/c target region
We then examined the methylation level of individual CpG islands of the miR-34b/c target region (Fig. 3C, Table 2 ). For miR-34b/c, some variability was observed in the methylation status of individual CpG units within the sequenced region. The results showed that the methylation rate of one CpG island (CpG_9.10) was lower in the STS group (mean methylation = 10.89%) than in the normal control group (mean methylation = 14.95%), and the methylation rates of the remaining three CpG units containing CpG_8, CpG_14, and CpG_15.16 (mean methylation = 19.05%, 23.02%, 14.88%, respectively) were numerically higher than those of the normal control group (mean methylation = 12.65%, 19.16%, 5.45%, respectively). Moreover, the methylation rate of three CpG islands of miR-34b/c (CpG_1.2.3, CpG_4.5.6.7, and CpG_11.12.13) was significantly higher in the STS group (mean methylation = 15.45%, 13.84%, 12.98%, respectively) than in the normal control group (mean methylation = 5.47%, 5.8%, 5.4%, respectively) (all the p values are less than 0.001).
We further evaluated whether the methylation level of individual CpG islands of miR-34b/c target region differed among the SRTS group, NRTS group, and normal control group (Fig. 3D, Table 3 ). We found heterogeneity between individual CpG units. The result showed that apart from CpG_9.10, the methylation level of six CpG units was numerically higher in samples of SRTSs and NRTSs than in the normal control. In addition, the mean methylation levels at CpG_1.2.3, CpG_4.5.6.7, and CpG_11.12.13 were significantly higher within SRTSs and NRTSs than in the normal control (p b 0.001). We found heterogeneity among individual CpG units. The association between the patterns of the quantitative methylation of every CpG unit within the miR-34b/c and the clinicopathologic features of the 57 patients with STSs was further evaluated (Table 4 ). The CpG_14 methylation levels of miR-34b/c in male tumor tissues were remarkably greater than those in female tumor tissues (27.29% vs. 17.17%, p = 0.047; two-tailed Mann-Whitney U-test). Moreover, the CpG_14 methylation levels of miR-34b/c were closely related to age, given that the methylation levels in patients over 45 years old were significantly higher than those in patients under 45 years old (29.05% vs. 18.70%, p = 0.034; two-tailed Mann-Whitney U-test). The CpG_9.10 methylation levels of miR-34b/c in STSs had a positive correlation with pathological grade (p = 0.039; two-tailed Kruskal-Wallis H test). The results also showed that the CpG_1.2.3 methylation levels of miR-34b/c were correlated with tumor size. Methylation levels were higher in tumors with diameters larger than 5.8 cm than in those less than 5.8 cm in diameter (p = 0.027; two-tailed Mann-Whitney U-test). The methylation levels of miR-34b/c in STSs were associated with clinical stage. The CpG_1.2.3, CpG_4.5.6.7, CpG_9.10, CpG_11.12.13, and CpG_14 methylation levels in tumor-stage III/IV tissues were also significantly higher than those in stage I/II tissues (31.36% vs. 12.04%, p = 0.002; 29.91% vs. 8.84%, p = 0.001; 24.06% vs. 3.74%, p b 0.001; 27.50% vs. 8.17%, p = 0.005; 35.08% vs. 18.15%, p = 0.020, respectively; two-tailed Mann-Whitney U-test, Fig. 4) . However, no correlation was found between the CpG unit methylation of miR-34b/c and the tumor location of STSs.
Discussion
We present a quantitative high-throughput assay for the methylation analysis of miR-34b/c within STSs by using the MassARRAY system. The MassARRAY system is a tool that enables high-throughput detection and quantitative analysis of methylation at one individual CpG site or CpG unit of a target nucleotide fragment. This tool generates precise data that represent the ratio of methylation events on individual CpG sites by MALDI-TOF MS. Genomic DNA converts the nonmethylated cytosine (C) into uracil (U), whereas methylated cytosine remains unchanged after bisulfite treatment. C/T changes are reflected as G/A changes in the cleavage products generated from the reverse strand by the base-specific cleavage reaction. These G/A changes will yield a mass difference of 16 Da for each CpG site, as precisely detected by the compact MassARRAY analyzer. In the mass spectrum, the relative amount of methylated DNA can be calculated by comparing the signal intensity between the mass signals of methylated and non-methylated templates to yield quantitative results for each cleavage product.
MiRNAs are essential post-transcriptional regulators that regulate gene expression by binding to partially complimentary sequences of target messenger RNAs (mRNA). The interaction leads to mRNA degradation or protein synthesis repression, resulting in protein expression downregulation of the target gene. Therefore, dysregulation of miRNAs can influence the expression of oncogenes or tumor suppressor genes. MiRNA34b/c, the transcriptional targets of tumor suppressor p53, has an important function in the p53 signaling network. The expression of miRNA34b/c is activated by p53 regulation, miR-34b/c has been indicated to have a tumor-suppressing property. Thus, miR-34b/c was shown to suppress tumor development by inhibiting several processes, including cell proliferation, apoptosis, metastasis, cell cycle, adhesionindependent colony formation, and epithelial-mesenchymal transition (Corney et al., 2007; Rokavec et al., 2014) . Epigenetic inactivation of miR-34b/c by DNA hypermethylation was identified in a number of different cancers and was confirmed to be related to tumorigenesis and pathogenesis.
Methylation of miR-34b/c was detected in primary lung adenocarcinoma (46%, 64/140) and lung adenocarcinoma cell lines (40%, 6/15). The expression of miR-34b/c was significantly reduced in all methylated primary tumors and cell lines, especially those with P53 mutations. MiR-34b/c methylation has independent prognostic value in patients with early-stage lung adenocarcinoma. The re-expression of miR-34b/ c results in a less aggressive phenotype in lung adenocarcinoma cell lines (Nadal et al., 2013) . Wu et al. showed that miR-34b/c methylation has been found in 80 of 82 (97.5%) colorectal cancer tissue samples, which suggests that the abnormal methylation of miR-34b/c genes might be regarded as a potential biomarker for the noninvasive screening and diagnosis of colorectal cancer (Wu et al., 2014) . In addition, Sanchita et al. reported that the promoter hypermethylation of miR34c contributed to the downregulated protein expression in colon cancer and that treatment with methyltransferase inhibitor resulted in the re-expression of miR-34c, which was attributed to the growth inhibition of both chemo-resistant and chemo-sensitive colon cancer cells. This finding suggested that the downregulation of this microRNA-34c may partly contribute to unregulated cellular growth and drug resistance in colon cancer (Roy et al., 2012) . Another study has shown that the frequency of miR-34b/c methylation was significantly higher in small-cell lung cancer (SCLC) than in non-small-cell lung cancer (NSCLC), miR-34b/c methylation promoted SCLC cell growth, invasion, and migration. Thus, the aberrant methylation of miR-34b/c is important in the pathogenesis of SCLC, which implies that miR-34b/c may be a useful therapeutic target for SCLC (Tanaka et al., 2012) . Similarly, miR-34b/c expression was inversely correlated with miR-34b/c methylation in chronic lymphocytic leukemia. MiR-34b re-expression by demethylation treatment resulted in the repression of cellular proliferation and increased cell death in MEC1 cells (Wang et al., 2014) . Moreover, a recent study identified that the abnormal methylation of miR-34b/c was associated with a high probability of recurrence as well as poor overall survival and disease-free survival. The promoter hypermethylation of miR-34b/c was an independent prognostic factor of stage I NSCLC (Wang et al., 2011) .
Compared with the relevant findings on cancer, the understanding of miR-34b/c methylation alterations in STSs remains very limited. In this work, we measured the quantitative DNA methylation patterns of miRNA34b/c CpG islands in STS tissues by using MALDI-TOF-MS. Hierarchical clustering suggested that the quantitative methylation patterns in sarcoma tissue exhibited substantive differences from those in the normal control group and the corresponding CpG units tend to cluster together in STS tissues and showed higher methylation patterns. The miR-34b/c gene was frequently methylated in STSs and the methylation level of miR-34b/c was significantly higher in STSs than in normal controls. This work is the first to evaluate the methylation level of individual CpG islands of miR-34b/c within STSs. We found that methylation level differed among individual CpG units, with the highest and lowest values being 23% and 10% in STS. Moreover, the methylation frequencies of three CpG islands of miR-34b/c (CpG_1.2.3, CpG_4.5.6.7 and CpG_11.12.13) were significantly higher in the STS group than in the normal control group (p b 0.001). Aberrant methylation was higher in SRTSs and NRTSs than in normal controls, the difference was statistically significant (p b 0.05). These results indicated that the hypermethylation of miR-34b/ c might be an important mechanism in STS pathogenesis. However, the methylation changes observed in SRTSs and NRTSs did not exhibit significant differences. In addition, we also observed that the methylation level of each CpG island was not significantly different between SRTSs and NRTS. The result suggested no association may exist between the methylation patterns of miR-34b/c and the characteristics of STS genetics.
Our results are similar to previous findings (Vogt et al., 2011) . Although the participants in both studies had different genetic and environmental backgrounds, Vogt et al. found a higher methylation level of miR-34b/c in STSs by using methylation-specific PCR methods (MSP), rather than the quantitative method. They showed that aberrant miR-34b/c methylation occurs in 45.45% (5/11) of the STS formalinfixed paraffin-embedded (FFPE) samples in cultured STS cells (40%,16/ 40) and in 75% (6/8) STS frozen tissue samples (Vogt et al., 2011) . In brief, with the application of the non-quantitative MSP approach to a German population and the quantitative MassARRAY method to a Chinese population, the consistency of the methylation of miR-34b/c CpG islands in both studies strengthens the association between miR-34b/c methylation and STSs. MiR-34b/c is reportedly subject to frequent inactivation by CpG methylation in various human malignant tumors (Beresneva et al., 2013; Nadal et al., 2013; Ng et al., 2014; Vogt et al., 2011; Wu et al., 2014) . However, our study is the first to demonstrate the aberrance methylation level of miR-34b/c in Chinese patients with STSs. DNA methylation, which is an enzymatically catalyzed modification of DNA during cellular differentiation and embryogenesis, is related to the modulation of genome function in response to life experiences and behavior and affects gene function and the phenotype. The modulations may serve as a mechanism for life-long genome adaptation and ethnic variations in DNA methylation levels involved in life experiences, such as lifestyle and dietary differences (Szyf, 2013; Szyf and Bick, 2013) . Methylation is an important epigenetic modification involved in biological processes such as gene expression regulation, DNA structure, and control of transposable elements in mammalian development and human diseases, including cancer (Liu et al., 2013; Varriale, 2014) . Existing studies have shown various STS-susceptible genes, such as BMP2 and ASS1 genes, with abnormal DNA methylation in STSs, and the methylation changes may be associated with the progression and prognosis of STSs (Huang et al., 2013; Wolf et al., 2014) . Another study suggested that p16 (INK4a) mRNA and protein expression downregulation due to hypermethylation of p16 (INK4a) promoter were observed in malignant progression within STSs and were associated with reduced patient survival (Knosel et al., 2014) . In this study, we found aberrant miR-34b/c methylation occurs in STSs, we further investigated the possible associations between aberrant methylation and clinical characteristics. To our knowledge, this study is the first to show that the DNA hypermethylation of miR-34b/c correlates with late clinical stage in patients with STSs. We conclude that patients with DNA hypermethylation of miR-34b/c had a high probability of poor prognosis. However, we failed to acquire available survival data. Our data show the significant association between overall methylation level of miRNA34b/c and gender, especially the CpG_14 methylation status was significantly higher in males than in females. However, there were 61.4% of male and 38.6% of female in our sample, male patients were more than female patients. Our data may require further experimental verification in order to ensure the accuracy of conclusion. The previous data shown that gender-specific DNA methylation existed in mice and humans (Penaloza et al., 2014; Piferrer, 2013) . The hypermethylation of RARB, KCNH5 and KCNH8 was found to be more frequent in females than in males in NSCLC (Hawes et al., 2010) . Another study showed that promoter methylation of miR-137 was associated with female gender in oral rinse samples (Langevin et al., 2010) . In our study, the study group is mix of various sarcoma subtypes, we acknowledged each with a very different inherent biological phenotype and behavior. For example, a dermatofibrosarcoma protuberan has very little metastatic potential vs. synovial sarcoma. We are curious to know whether hypermethylation of miR-34b/c was associated with STS different subtypes or STSs with more aggressive behavior. But it is regretful that there was no significant association between overall methylation level of miRNA34b/c and tumor subtypes. It may indicate that methylation of miR-34b/c has nothing to do with the subtype of STSs, and may also the samples are likely too small that they have no trend. Age is an important factor for tumorigenesis. Our data show that the CpG_14 methylation levels of miR-34b/c were markedly higher in senile patients. In addition, we found that CpG_1.2.3 methylation levels were positively correlated with tumor size. In our study, we found that CpG_9.10 methylation status had a positive correlation with pathological grade, indicating that DNA hypermethylation of miR-34b/c within CpG_9.10 might be an important prognostic parameter. These findings support the idea that the hypermethylation of miR34b/c might be correlated with the progression and prognostic of STSs. However, our sample numbers are likely too small, further studies with larger samples have to be conducted to confirm our observation.
DNA methylation is an important method of epigenetic modificative regulation, which subsequently results in transcriptional inhibition and expression silencing of target gene. This process is an important element in the regulation of various factors implicated in tumor development. Strong evidence demonstrates a positive correlation between the appearance of target gene methylation and the reduction in the level of target protein expression (Bauer et al., 2010; Rodriguez-Paredes and Esteller, 2011) . Previous studies have shown that hypermethylation of miR-34b/c contributed to the down-regulation protein expression in lung adenocarcinoma, colon cancer and chronic lymphocytic leukemia (Nadal et al., 2013; Roy et al., 2012; Wang et al., 2014) . In the present study, aberrant miR-34b/c methylation occurs in STSs, it has been hypothesized that miR-34b/c hypermethylation was related to the down-regulation of miR-34b/c gene expression. Further studies are needed to confirm whether the aberrant methylation of miR-34b/c influenced the expression level of miR-34b/c in STSs. The alterations of tumor suppressor p53 pathway are highly connected with various types of human cancers, plays a significant role in preventing tumor development and progression mostly through its downstream target genes (Liao et al., 2014) . The promoter regions of miR-34b/c include a palindromic sequence that matches the canonical p53-binding site, miR-34b/c expression may be induced by P53 in response to DNA damage or cell stress (Wei et al., 2006) . MiR-34b/c is a direct target of p53, our study revealed a novel mechanism for miR34b/c regulation in STSs. According to previous data, expression of miR-34b/c was significantly down-regulated in methylated lung adenocarcinoma primary tumors and cell lines, especially in those harboring a P53 mutation (Nadal et al., 2013) . Recently, the date showed that p53 mutations occur in STSs, p53 mutations were detected in 40.0% of NRTSs and 13.0% SRTS. The frequency of p53 mutations was significantly higher in cases with NRTSs than in cases with SRTS (Yin et al., 2012) . Although no statistical differences were observed in miR-34b/c methylation level between SRTSs and NRTSs in our study, we found that methylation level was higher in NRTSs than in SRTSs. Thus, it was considered whether there are any relationship between p53 mutations and miR34b/c hypermethylation in STSs. Clearly, further studies are required to obtain a more complete understanding of association between P53 mutational status and miR-34b/c methylation in STSs. In addition, no study has confirmed whether dysregulated miR-34b/c can affect STS progression. Therefore, the biological function of the miR-34b/c hypermethylation in STSs should be further analyzed to clarify this point by mechanistic experiments.
Conclusion
This study illustrates that the hypermethylation of miR-34b/c CpG islands is a relatively common event in STSs and is significantly correlated with late clinical stage in patients with STSs. These findings indicate that the hypermethylation of the miR-34b/c may be pivotal to the oncogenesis and development of STSs and may be a potential prognostic factor for STSs.
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